- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06188208
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
June 17, 2024 updated by: Vividion Therapeutics, Inc.
A Phase 1, Open-Label, 2-Part, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of the STAT3 Inhibitor VVD-130850 as Single Agent and in Combination With Checkpoint Inhibition in Participants With Advanced Solid and Hematologic Tumors
A FIH study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VVD-130850, as single agent and in combination with checkpoint inhibition, in participants with advanced solid and hematologic tumors.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
160
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Vividion Clinical Trial Call Center
- Phone Number: (858) 345-9752
- Email: clinicaltrials@vividion.com
Study Locations
-
-
-
Adelaide, Australia
- Recruiting
- Cancer Research South Australia
-
South Brisbane, Australia
- Recruiting
- ICON Cancer Research
-
-
-
-
-
Barcelona, Spain
- Recruiting
- START Barcelona Hospital HM Nou Delfos
-
Madrid, Spain
- Recruiting
- START Madrid CIOCC
-
-
-
-
Texas
-
Austin, Texas, United States, 78758
- Recruiting
- NEXT Austin
-
Houston, Texas, United States, 77030
- Recruiting
- MDACC
-
Irving, Texas, United States, 75039
- Recruiting
- NEXT Dallas
-
San Antonio, Texas, United States, 78299
- Recruiting
- NEXT San Antonio
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Recruiting
- Next Virginia
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
- Histologically or cytologically confirmed metastatic or unresectable solid tumor or advanced non-Hodgkin's lymphoma (NHL).
- Eastern Cooperative Oncology Group (ECOG) performance status ≤1.
- Adequate organ and bone marrow function as defined in the protocol.
For Combination Therapy Expansion:
- Serine/threonine kinase 11/ liver kinase B1 (STK11/LKB1) mutated non-small cell lung cancer (NSCLC) as assessed by historical (local) test.
- Must be refractory to or have progressed on or after a platinum-based doublet regimen and an immune checkpoint inhibitor (CPI). These therapies could have been given in the same line of therapy or different lines of therapy.
- Measurable disease by RECIST version 1.1 as assessed by the Investigator.
Key Exclusion Criteria:
- Have a diagnosis of immunodeficiency or are receiving systematic steroid therapy or any other form of immunosuppressive therapy.
- Prior allogeneic transplantation.
- History of cardiac diseases as defined in detail in the protocol.
- Clinically significant infection or any eye infection.
- Active central nervous system (CNS) malignancies (previously treated CNS malignancies are not exclusionary).
Combination Therapy Expansion:
- Known hypersensitivity or contraindication to pembrolizumab or any of its components.
- Any prior toxicity (Grade 3 or 4) related to immunotherapy leading to treatment discontinuation with the exception of the history of immunotherapy-related endocrinopathy controlled with ongoing medical management (e.g., hypothyroidism, adrenal insufficiency, diabetes).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Escalation: VVD-130850 Single Agent
Participants will receive ascending doses of VVD-130850, orally, once daily in 21-day treatment cycles during the dose escalation phase.
|
Oral tablets
|
Experimental: Dose Escalation: VVD-130850 + Pembrolizumab Combination Therapy
Participants will receive ascending doses of VVD-130850, orally, once daily, along with pembrolizumab intravenous (IV) infusion, every 3 weeks (Q3W) in 21-day treatment cycles during the dose escalation phase.
|
IV infusion
Oral tablets
|
Experimental: Dose Expansion: VVD-130850 Single Agent
Participants will receive VVD-130850 at recommended dose for expansion (RDE), orally, once daily in 21-day treatment cycles during the dose expansion phase.
|
Oral tablets
|
Experimental: Dose Expansion: VVD-130850 + Pembrolizumab Combination Therapy
Participants will receive VVD-130850 at RDE orally, once daily along with pembrolizumab IV infusion, Q3W in 21-day treatment cycles during the dose expansion phase.
|
IV infusion
Oral tablets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose Escalation: Incidence and Severity of Dose-limiting Toxicities (DLTs) During DLT Observation Period
Time Frame: From Day 1 to Day 21 of Cycle 1 [cycle length=21 days]
|
Incidence and severity of DLTs will be assessed per DLT criteria set forth in the protocol based on adverse events (AEs) evaluated per National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
|
From Day 1 to Day 21 of Cycle 1 [cycle length=21 days]
|
Dose Expansion: Number of Participants with AEs and Serious Adverse Events (SAEs)
Time Frame: Up to approximately 4 years
|
Up to approximately 4 years
|
|
Dose Expansion: Number of Participants with Clinically Significant Changes in Vital Signs
Time Frame: Up to approximately 4 years
|
Up to approximately 4 years
|
|
Dose Expansion: Number of Participants with Clinically Significant Changes in Laboratory Evaluations
Time Frame: Up to approximately 4 years
|
Up to approximately 4 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose Escalation: QT/Corrected QT (QTc) Interval and Other Electrocardiogram (ECG) Parameters
Time Frame: Up to approximately 4 years
|
Number of participants with changes in QT/QTc interval and other ECG parameters will be assessed.
|
Up to approximately 4 years
|
Dose Escalation: Recommended Dose for Expansion (RDE) of VVD-130850 as a Single Agent and in Combination with Pembrolizumab
Time Frame: Up to approximately 4 years
|
The RDE will be based on safety, pharmacokinetics, pharmacodynamic biomarker data, and preliminary anti-tumor activity collected during the study as defined by the safety review committee.
|
Up to approximately 4 years
|
Dose Expansion: Overall Response Rate (ORR)
Time Frame: Up to approximately 4 years
|
ORR is defined as the percentage of participants achieving a best overall response of complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator assessment.
|
Up to approximately 4 years
|
Dose Expansion: Duration of Response (DoR)
Time Frame: Up to approximately 4 years
|
DOR is defined as the time from initial response of CR or PR to progressive disease or death, whichever comes first per RECIST version 1.1 by investigator assessment.
|
Up to approximately 4 years
|
Dose Expansion: Progression-free Survival (PFS)
Time Frame: Up to approximately 4 years
|
PFS is defined as the time from the date of randomization to the time of confirmed disease progression or death, whichever occurs first per RECIST version 1.1 by investigator assessment.
|
Up to approximately 4 years
|
Dose Expansion: Disease Control Rate (DCR)
Time Frame: Up to approximately 4 years
|
DCR is defined as the percentage of participants achieving CR or PR, or stable disease (SD) per RECIST version 1.1 by investigator assessment.
|
Up to approximately 4 years
|
Dose Escalation and Expansion: Area Under the Plasma Concentration-time Curve (AUC) of VVD-130850
Time Frame: Predose and multiple timepoints post-dose from Cycle 1 Day 1 up to Cycle 5 Day 1 (cycle length=21 days)
|
Predose and multiple timepoints post-dose from Cycle 1 Day 1 up to Cycle 5 Day 1 (cycle length=21 days)
|
|
Dose Escalation and Expansion: Maximum Plasma Concentration (Cmax) of VVD-130850
Time Frame: Predose and multiple timepoints post-dose from Cycle 1 Day 1 up to Cycle 5 Day 1 (cycle length=21 days)
|
Predose and multiple timepoints post-dose from Cycle 1 Day 1 up to Cycle 5 Day 1 (cycle length=21 days)
|
|
Dose Escalation and Expansion: Apparent Terminal Half-life (t1/2) of VVD-130850
Time Frame: Predose and multiple timepoints post-dose from Cycle 1 Day 1 up to Cycle 5 Day 1 (cycle length=21 days)
|
Predose and multiple timepoints post-dose from Cycle 1 Day 1 up to Cycle 5 Day 1 (cycle length=21 days)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 5, 2024
Primary Completion (Estimated)
December 1, 2027
Study Completion (Estimated)
December 1, 2027
Study Registration Dates
First Submitted
December 13, 2023
First Submitted That Met QC Criteria
December 31, 2023
First Posted (Actual)
January 3, 2024
Study Record Updates
Last Update Posted (Actual)
June 18, 2024
Last Update Submitted That Met QC Criteria
June 17, 2024
Last Verified
June 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VVD-130850-01
- 2023-508386-32-00 (Other Identifier: EU CTIS Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Genentech, Inc.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsCanada, Korea, Republic of, United States, Brazil, Australia, Argentina, Spain, New Zealand, Poland
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
University of AlbertaWithdrawnLocally Advanced Solid Tumors | Metastatic Solid TumorsCanada
Clinical Trials on Pembrolizumab
-
Acerta Pharma BVMerck Sharp & Dohme LLCCompletedMetastatic Urothelial CarcinomaUnited States
-
Incyte CorporationMerck Sharp & Dohme LLCCompletedMelanomaUnited States, France, Italy, United Kingdom, Spain, Belgium, Israel, Mexico, Japan, Canada, Netherlands, Sweden, Korea, Republic of, Australia, Russian Federation, Chile, Germany, Poland, Ireland, New Zealand, Denmark, Switzerland, South Africa
-
HUYABIO International, LLC.Active, not recruitingNon Small Cell Lung CancerUnited States
-
Prof. Dr. Matthias PreusserUnknownPrimary Central Nervous System LymphomaAustria
-
Merck Sharp & Dohme LLCCompletedMelanomaAustralia, South Africa, Spain, Sweden
-
Yonsei UniversityNot yet recruitingMucosal Melanoma | Acral MelanomaKorea, Republic of
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Merck Sharp & Dohme LLC; PTC TherapeuticsRecruitingColorectal Cancer | Endometrium CancerNetherlands
-
Michael BoyiadzisMerck Sharp & Dohme LLCCompletedAcute Myeloid LeukemiaUnited States
-
University of UtahMerck Sharp & Dohme LLCTerminatedNeuroendocrine TumorsUnited States
-
The University of Hong KongMerck Sharp & Dohme LLCUnknown